ArticleJournal of animal science2026
Effects of potentiated zinc oxide and crude protein levels in low acid-binding capacity diets on growth performance and mineral status in nursery pigs.
Article in Journal of animal science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A total of 360 weanling barrows (DNA 200 × 400; initial BW 5.90 ± 0.03 kg) were used in a 38-d study to evaluate the effects of a potentiated zinc oxide (pZnO) and different crude protein (CP) levels on performance and mineral status. The diets were formulated with a low acid-binding capacity at pH 4 (ABC-4). Pens were randomly assigned to treatments while ensuring that mean initial body weight was balanced across dietary treatments: phase 1 (d 0 to 10), phase 2 (d 11 to 24), and phase 3 (d 25 to 38). All diets were formulated with low ABC-4 values. Treatments included a negative control (NC; 21.3% CP, 150 mg/kg Zn from pZnO), a positive control (PC; 3,000 mg/kg Zn in phase 1, 2,000 mg/kg in phase 2 from ZnO), and four experimental groups receiving pZnO at either 500 or 800 mg/kg in phase 1, and 300 or 500 mg/kg in phase 2, with or without CP reduction to 19.3% in phase 1 and 19.4% in phase 2 (pZ500, pZ500-LCP, pZ800, pZ800-LCP). In phase 3, all pigs received a common diet (21.2% CP, 150 mg/kg Zn from pZnO). During phase 1, pigs fed the pZ800 diet showed improved average daily gain (ADG), feed intake (ADFI), and gain-to-feed ratio (G:F; P ≤ 0.05) compared to NC. A linear dose-response effect of pZnO was observed for ADG, ADFI, and G:F (P < 0.05). From d 0 to 24 (experimental period), pigs fed low-CP diets (particularly pZ800-LCP) had poorer (P < 0.05) G:F than pigs fed higher-CP diets, despite similar or increased feed intake. Linear improvements in ADG and ADFI were observed with increasing pZnO (P ≤ 0.024). Across the trial, when pigs were fed 800 mg/kg pZnO, lower CP reduced (P < 0.05) G:F compared to pigs fed the pZ800 treatment. Pigs fed low CP diets had greater (P = 0.008) fecal dry matter content. Tissue and serum zinc concentrations increased (P < 0.05) with dietary ZnO. Pigs fed the PC treatment resulted in the highest serum and liver Zn levels at d 24 and 38, while liver manganese was significantly reduced in both PC and pZ800-LCP compared to NC (P < 0.05). Expression of zinc transporter ZIP4 was downregulated in PC and pZ800, whereas metallothionein and ZnT2 were upregulated in PC compared to NC (P < 0.05). In conclusion, potentiated ZnO at moderate concentrations maintained similar performance compared to pharmacological ZnO. Lowering crude protein levels, while improving fecal consistency, compromised feed efficiency, underscoring the importance of maintaining adequate amino acid supply in multifactorial feeding strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.